Aerie Pharmaceuticals Elects Murray Goldberg to the Company's Board of Directors

EDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. announced today that Murray Goldberg has been elected to the Company's Board of Directors, effective August 19, 2013. Mr. Goldberg has had a successful career in corporate finance and banking, and he has served as Chief Financial Officer of Regeneron Pharmaceuticals, Inc. since 1995. With the election of Mr. Goldberg to Aerie's Board, the Company's directors now number eight.

"Murray Goldberg brings diverse financial experience and invaluable expertise having played a critical role in growing a leading life sciences firm with a major ophthalmology product on the market," stated Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of Aerie Pharmaceuticals. "We are pleased to welcome Murray to the Aerie Board and look forward to his contributions to our continuing progress."

As Chief Financial Officer at Regeneron, Mr. Goldberg is responsible for managing all facets of the company's financial activities and has contributed to the strategic success of the company and generation of significant shareholder value. During his tenure, Regeneron advanced from being an early-stage public company to a commercial organization with three products on the market, including EYLEA® (aflibercept) Injection, an innovative therapy for patients with neovascular (wet) age-related macular degeneration (AMD). Prior to joining Regeneron, Mr. Goldberg was Vice President, Finance, Treasurer, Chief Financial Officer and a Director of the private biotechnology company PharmaGenics, Inc. Previously, Mr. Goldberg was Managing Director, Structured Finance Group at the Chase Manhattan Bank, N.A., and prior to this, he served in various managerial positions in finance and corporate development at American Cyanamid Company. Mr. Goldberg received his M.B.A. degree from the University of Chicago, his M.Sc. degree in Economics from the London School of Economics, and his B.E. degree in Industrial Engineering from New York University.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals is a privately held pharmaceutical company in late Phase 2 dedicated to the discovery and development of novel small-molecule treatments for glaucoma. Aerie's internal research and development engine has generated an innovative glaucoma pipeline of proprietary product candidates, which are well tolerated, high efficacy, once-daily eye drop therapies that include the first new mechanisms of action for glaucoma treatment in nearly 20 years.

The Company's lead product candidate, AR-13324, is the first of a new dual action drug class that reduces the eye's fluid inflow while also increasing fluid outflow through the trabecular meshwork, which is the eye's main fluid drain, all in a highly effective single drop per day. Aerie's PG324 fixed combination of AR-13324 with latanoprost is a first-in-class glaucoma therapy to lower intraocular pressure by reducing fluid inflow while also opening both of the eye's fluid drains. This product candidate offers the convenience of two drugs in one eye drop.

Aerie is located in Bedminster, New Jersey and Research Triangle Park, North Carolina. Further information on the Company is available at www.aeriepharma.com.

Contacts

Aerie Pharmaceuticals
Richard Rubino, (908) 470-4320
[email protected]
or
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Justin Jackson, (212) 213-0006
[email protected]

 

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.